Pfizer raises 2025 profit forecast for second time in a row
Nov 4 (Reuters) - Pfizer PFE.N lifted its full-year profit forecast for the second time in a row on Tuesday, buoyed by strong demand for its blockbuster heart treatment and blood thinner. The company said it expects adjusted earnings of $3.00 to $3.15 per share, up from its prior view of $2.90 to $3.10. (Reporting by Mrinalika Roy and Christy Santhosh in Bengaluru; Editing by Saumyadeb Chakrabarty) ((mrinalika.roy@thomsonreuters.com;))
Recent news on Metsera
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up